This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Baker, C. A. R. Articles by Huyen Cao Search for Related Content PubMed PubMed Citation Articles by Baker, C. A. R. Articles by Huyen Cao, Social Bookmarking                         What's this?

HIV Subtypes Distribution and Implication for Antiretroviral Treatment in a Ugandan Population

California Department of Health Services, Richmond, Chris.Baker{at}cdph.ca.gov

Stephanie Bousheri, BS

California Department of Health Services, Richmond

Isaac Ssewanyana, BS

Joint Clinical Research Centre, Kampala

Norman G. Jones, BS

California Department of Health Services, Richmond

Okumu K'Aluoch, MSc

California Department of Health Services, Richmond

David Baliruno, BS

Joint Clinical Research Centre, Kampala

Francis Ssali, MD

Joint Clinical Research Centre, Kampala

Huyen Cao, MD

California Department of Health Services, Richmond

References

• Kaleebu P., Ross A., Morgan D., et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS. 2001;15(3):293-299.[CrossRef][Medline] [Order article via Infotrieve]
• Kaleebu P., French N., Mahe C., et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis. 2002;185(9):1244-1250.[CrossRef][Medline] [Order article via Infotrieve]
• Richard N., Juntilla M., Abraha A., et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2004;20(4):355-364.[CrossRef][Medline] [Order article via Infotrieve]
• Nijhuis M., Schuurman R., de Jong D., et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999;13(17):2349-2359.[CrossRef][Medline] [Order article via Infotrieve]
• Erickson JW, Gulnik SV, Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS. 1999;13(Suppl A):S189-S204.[Medline] [Order article via Infotrieve]
• Vergne L., Peeters M., Mpoudi-Ngole E., et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38(11):3919-3925.[Abstract/Free Full Text]
• Solomon A., Cameron PU, Bailey M., et al. Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. J Infect Dis. 2003;187(12):1915 -1923.[CrossRef]
• Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17(13):1881-1888.[CrossRef][Medline] [Order article via Infotrieve]
• Liu Z., Cumberland WG, Hultin LE, Prince HE, Detels R., Giorgi JV Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(2):83-92.[Medline] [Order article via Infotrieve]
• Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859-870.[CrossRef][Medline] [Order article via Infotrieve]
• Bruce C., Clegg JC, Featherstone A., et al. Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda. AIDS Res Hum Retroviruses. 1994;10: 1543-1550.[Medline] [Order article via Infotrieve]
• Hoelscher M., Dowling WE, Sanders-Buell E., et al. Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay. AIDS. 2002;16:2055-2064.[CrossRef][Medline] [Order article via Infotrieve]
• Hu DJ, Dondero TJ, Rayfield MA, et al. The emerging genetic diversity of HIV: the importance of global surveillance for diagnostics, research and prevention. JAMA. 1996;275:210-216.[Abstract/Free Full Text]
• Eggena MP, Barugahare B., Okello M., et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis. 2005;191(5):694-701.[CrossRef][Medline] [Order article via Infotrieve]
• Barugahare B., Baker C., K'Aluoch O., et al. Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition. J Virol. 2005;79(7):4132-4139.[Abstract/Free Full Text]
• Rizzardini G., Piconi S., Ruzzante S., et al. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS. 1996; 10(13):1535-1542.[Medline] [Order article via Infotrieve]
• Eggena MP, Barugahare B., Jones N., et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005;174(7):4407-4414.[Abstract/Free Full Text]
• Kantor R., Katzenstein DA, Efron B., et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2(4):e112.[CrossRef][Medline] [Order article via Infotrieve]
• Spira S., Wainberg MA, Loemba H., Turner D., Brenner BG Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003;51(2):229-240.[Abstract/Free Full Text]
• Weidle PJ, Malamba S., Mwebaze R., et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360(9326): 34-40.[CrossRef][Medline] [Order article via Infotrieve]
• Palmer S., Margot N., Gilbert H., Shaw N., Buckheit R. Jr, Miller M. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses. 2001;17(12):1167-1173.[CrossRef][Medline] [Order article via Infotrieve]
• Dumans AT, Soares MA, Machado ES, et al. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis. 2004;189(7):1232-1238.[CrossRef][Medline] [Order article via Infotrieve]
• Frater J. The impact of HIV-1 subtype on the clinical response on HAART. J HIV Ther. 2002;7(4):92-96.[Medline] [Order article via Infotrieve]
• Loemba H., Brenner B., Parniak MA, et al. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res. 2002;56(2):129-142.[CrossRef][Medline] [Order article via Infotrieve]
• Katzenstein TL Molecular biological assessment methods and understanding the course of the HIV infection. APMIS Suppl. 2003(114):1-37.
• Hazenberg MD, Otto SA, Wit FW, Lange JM, Hamann D., Miedema F. Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss. AIDS. 2002;16(9):1287-1289.[CrossRef][Medline] [Order article via Infotrieve]
• Sufka S., Ferrari G., Gryszowka V., et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis. 2003;187:1027-1037.[CrossRef][Medline] [Order article via Infotrieve]

This version was published on December 1, 2007

Journal of the International Association of Physicians in AIDS Care (JIAPAC), Vol. 6, No. 4, 260-263 (2007)
DOI: 10.1177/1545109707303938


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Baker, C. A. R. Articles by Huyen Cao Search for Related Content PubMed PubMed Citation Articles by Baker, C. A. R. Articles by Huyen Cao, Social Bookmarking                         What's this?